Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

NORCROSS, Ga., March 29, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2012. These results are included in the Company's Quarterly Report on Form 10-K, which has been filed with the SEC.

"It was a year of great progress for our Company," said Peter G. Traber , M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "We completed a significant fundraising and our stock was listed on the NASDAQ Capital Market earlier in the year, we relocated our headquarters to Norcross, Georgia during the fourth quarter, and we made significant advances developing our fibrosis program. We have continued this progress into 2013, having submitted an IND for GR-MD-02 in January and received the FDA's ok that we could proceed with a Phase 1 clinical trial. We expect to initiate a Phase 1 clinical trial of GR-MD-02 during the second quarter of 2013 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and have engaged CTI Clinical Trial Services to provide services related to this trial. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic options."

At December 31, 2012, the Company had $9.4 million of non-restricted cash and cash equivalents available to fund future operations.  The Company believes that with the funds on hand at December 31, 2012, there is sufficient cash to fund core operations and planned research and development through the first quarter of 2014.

For the fourth quarter of 2012, the Company reported a net lo
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... BOSTON , Aug. 27, 2014 Rhythm, ... diseases and genetic deficiencies that result in metabolic disorders, ... on Form S-1 with the U.S. Securities and Exchange ... of shares of its common stock. The number of ... the offering have not yet been determined. ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
(Date:8/27/2014)... of nature,s mysteries is how plants survive impact ... the sun,s rays, while using this energy for ... in the plant,s blades quickly dissipate the energy ... quakes. Researchers at DTU Physics have now managed ... algae and bacteria contain light-absorbing proteins which play ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Chelating ... About Chelating Agent A chelating ... covalent bonds with metal ions, thereby forming a ... some metal-ions have on chemical processes, formulations, and ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7DTU researchers film protein quake for the first time 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4
... Alfalight , a firm that makes high-power ... has established ties with Chinese distributor Sanetronic Company ... Hong Kong. The company was founded in 1987 as ... has eight offices in China, including Beijing, Shanghai, Shenzhen, ...
... research, nanotechnology, farm waste management and produce storage have emerged ... Transfer Award. , ,Judges for the contest have winnowed the ... The $5,000 grand prize will be presented to the winner ... in Milwaukee. , ,The finalists are: , , GHD ...
... The Joint Finance Committee rejected Governor Jim Doyle's proposal for ... The proposal, a plan to charge consumers for their music, ... several proposals turned down by the budget review panel. , ... on electronic entertainment called by some detractors the "iPod ...
Cached Biology Technology:Five remaining firms vie for Tech Transfer award 2Five remaining firms vie for Tech Transfer award 3Finance Committee rejects extra tax on Internet buys 2Finance Committee rejects extra tax on Internet buys 3
(Date:8/27/2014)... effective doses of the HIV drug maraviroc, a new ... completed before the drug was licensed in 2007, included ... key to removing maraviroc from the body. The current ... protein including nearly half of African-Americans end ... those who lack the protein even when given the ...
(Date:8/27/2014)... neural circuits in the brain of mice, scientists ... The research, led by Howard Hughes Medical Institute ... Technology (MIT), reveals that the connections between the ... about an experience and the part of the ... experience are malleable. , Altering those connections ...
(Date:8/27/2014)... to listen carefully to someone, the first thing we ... is stop moving altogether. This strategy helps us hear ... movements. , This interplay between movement and hearing also ... evidence has long suggested that the brain,s motor cortex, ... gives rise to our conscious perception of sound. , ...
Breaking Biology News(10 mins):Dosage of HIV drug may be ineffective for half of African-Americans 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3
... ORLANDO, Fla. Soy food consumption did not ... survivors of breast cancer, according to the results of ... 2011, held April 2-6. Researchers investigated the association ... survivors, using data from a multi-institution collaborative study, the ...
... America (ESA) has selected 37 insect-science symposia for its ... http://entsoc.org/entomology2011 ). The symposia will address important ... Disorder, insect control, invasive species, medical and veterinary entomology, ... BEES AND COLONY COLLAPSE DISORDER Bee ...
... premature aging of immune cells, which may make people more ... new UCSF-led study. The findings indicate that accelerated ... is dependent upon how long someone is depressed, particularly if ... March 2011 by the journal PLoS One and ...
Cached Biology News:Soy isoflavones not a risk for breast cancer survivors 2Entomology 2011 symposia selected 2Entomology 2011 symposia selected 3Study finds link between chronic depression and accelerated immune cell aging 2Study finds link between chronic depression and accelerated immune cell aging 3
... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: surface area 500 cm 2 ...
... Ideal for cell culture scale-up, these ... 10 7 - 10 9 range ... bottles or spinner flasks. • High mechanical ... leak tested prior to shipping • Certified ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Biology Products: